Shopping Cart
Remove All
Your shopping cart is currently empty
CC-401 is a specific inhibitor of JNK (Ki: 25-50nM).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $383 | 35 days | 35 days | |
| 5 mg | $1,680 | 35 days | 35 days | |
| 10 mg | $2,870 | 35 days | 35 days |
| Description | CC-401 is a specific inhibitor of JNK (Ki: 25-50nM). |
| Targets&IC50 | JNK:25-50 nM (Ki) |
| In vitro | CC-401 is a second-generation ATP-competitive inhibitor of all three forms of JNK. It is selective against JNK over other kinases such as p38, ERK, IKK2, and ZAP70. CC-401 potently inhibits JNK in cell-based assay with a concentration of 1 to 5μM. The activation of JNK signaling is identified in many immune-mediated kidney disease models. Thus, as the JNK inhibitor, CC-401 is found to be effective in these renal injury models. In the acute anti-GBM disease, CC-401 inhibits JNK activation and causes a 50%-70% reduction of proteinuria. In addition, CC-401 is also used in liver injury models [1][2][3]. |
| Molecular Weight | 388.47 |
| Formula | C22H24N6O |
| Cas No. | 395104-30-0 |
| Smiles | N=1N=C(NC1)C2=CC=C3NN=C(C=4C=CC=C(OCCN5CCCCC5)C4)C3=C2 |
| Relative Density. | 1.275 g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO: ≥19.4 mg/mL, Sonication is recommended. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.